Hereditary angioedema (HAE) is an immune system disease that affects a small number of people. The absence of C1-esterase inhibitor (C1-INH) causes the blood arteries to widen, resulting in a life-threatening disease. Recurrent episodes of edoema in various body regions, such as the hands, feet, face, and airways, are among the disease’s symptoms. HAE is categorized into 3 types: Type I HAE, Type II HAE and Type III HAE based on the reduction in its manufacture of an inhibitor or the development of a defective protein. Although the illness is hereditary, the lack of a family history does not rule out the diagnosis of HAE, indicating that as many as 25 percent of HAE cases originate from a spontaneous mutation of the C1-inhibitor gene at conception.
Get PDF Brochure with COVID19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-pdf/1292
The global hereditary angioedema market had a market valuation of US$ 1,563.7 million in 2016 and is projected to grow at a CAGR of 9.1 percent during the forecast period (2017 – 2025).
The rising number of instances of hereditary angioedema, as well as the disease’s hereditary character, which allows the disease to pass the faulty gene down to future generations, are projected to drive the global hereditary angioedema market expansion. According to a 2015 survey conducted by the International Hereditary Angioedema Organization (HAEi), the global prevalence of hereditary angioedema is estimated to be between 1 in 10,000 and 50,000 people, implying that approximately a quarter million people worldwide suffer from this rare and life-threatening deficiency condition. According to the National Association for Rare Disorders, the risk of transmitting the faulty gene from afflicted parent to children is 50 percent for each pregnancy, regardless of the sex of the resulting kid, according to the National Association for Rare Disorders, 2016. Due to the larger number of medicines approved in the area, the presence of significant manufacturers, and the existence of numerous organizations, North America dominates the global hereditary angioedema market. The U.S. ranked first in the world in 2017. The Food and Drug Administration (FDA) has authorized CSL Behring’s Haegarda for regular prophylaxis in adolescence clients to avoid HAE episodes.
Considering the rarity of the disease, it is difficult to establish an accurate diagnosis and thus must rely on alternative medicines to control it, which is one of the key issues limiting the global hereditary angioedema market growth.
The global hereditary angioedema market is anticipated to spur as non-profit organizations increase their funding for intense research. The groups are concentrating on raising worldwide HAE awareness by educating and empowering patients and facilitating access to appropriate therapy and treatment. Efforts are also being made by the groups to do extensive research in order to find a cure. HAEi is a non-profit organization committed to raising awareness of C1-inhibitor deficits and improving diagnosis, as well as facilitating payment of HAE treatments and ensuring physical wellbeing for worldwide sufferers. In 2015, the charity launched the HAEi GAP, which aims to offer access to authorized HAE medicines in countries where contemporary treatments are otherwise inaccessible. Furthermore, the US Hereditary Angioedema Association, a non-profit organization, is dedicated to advancing and conducting clinical research to enhance the lives of HAE sufferers.
Key companies contributing in the global hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Pharming Healthcare, Inc., Shire Plc., CSL Behring, Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals, Inc.Attune Pharmaceuticals, Inc.
Purchase This Premium Report Here With Discounted Price (Flat US $2000 Off) – https://www.coherentmarketinsights.com/promo/buynow/1292
Reasons to Purchase this Report
• Current and future of global Hereditary Angioedema market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027